RAD Advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
Key points
- Positive recommendation from DSMC to advance to Cohort 4
- Next dose level of 180mCi for patients with HER2+ solid tumors
- Previous study showed positive safety and biodistribution
Full summary
Radiopharm Theranostics has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 180mCi in the Phase 1 'HEAT' clinical trial. The trial is focused on patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. This advancement follows a previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients, which demonstrated clinical proof-of-concept with positive safety and biodistribution.
Outlook
The DSMC's recommendation supports the favorable safety profile observed to date and allows us to continue evaluating higher dose levels in patients with HER2-positive advanced solid tumors.
Summary generated by a large language model. Please interpret with care.